Determination of the Apoptotic Effect and Molecular Docking of Benzamide Derivative XT5 in K562 Cells

ÖZKAN T., Hekmatshoar Y., ERTAN BOLELLİ T., Hidavat A. N., Beksac M., Aki-Yalcin E., ...Daha Fazla

ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, cilt.18, sa.11, ss.1521-1530, 2018 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 18 Sayı: 11
  • Basım Tarihi: 2018
  • Doi Numarası: 10.2174/1871520618666171229222534
  • Dergi Adı: ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.1521-1530
  • Anahtar Kelimeler: CML, K562, imatinib resistance, benzamide, apoptosis, CHRONIC MYELOID-LEUKEMIA, BIOLOGICAL EVALUATION, BENZOXAZOLES, IMATINIB, INHIBITORS, MECHANISM
  • Ankara Üniversitesi Adresli: Evet

Özet

Background: The tyrosine kinase inhibitor, imatinib, used as a first line treatment in Chronic Myeloid Leukemia (CML) patients, may lead to resistance and failure to therapy. Novel combinations of imatinib with other drugs is a strategy to improve treatment efficiency.